false000100604500010060452023-05-112023-05-11

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FORM 8-K CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	May 11, 2023
(Date of Report (date of earliest event reported)
IRIDEX CORPORATION
(Exact name of registrant as specified in its charter)
Delaware		000-27598	77-0210467
(State or other jurisdiction of incorporation or organization)		(Commission File Number)	(I.R.S. Employer Identification Number)
1212 Terra Bella Avenue Mountain View, California 94043
(Address of principal executive offices, including zip code)
(650) 940-4700
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of Class		Trading Symbol		Name of Exchange on Which Registered
Common Stock, par value $0.01 per share		IRIX		Nasdaq Global Market

 

 

---

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On May 11, 2023, IRIDEX Corporation issued a press release discussing its financial results for its first fiscal quarter of fiscal year 2023, which ended on April 1, 2023. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

 

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

(d)	Exhibits

 

Exhibit No.		Description
99.1		Press Release dated May 11, 2023.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

-2-

---

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

			IRIDEX CORPORATION
	By:		/s/David I. Bruce
			David I. Bruce
			President and Chief Executive Officer
Date: May 11, 2023

 

-3-

---

 

Exhibit 99.1

 

Iridex Reports First Quarter 2023 Financial Results

 

MOUNTAIN VIEW, Calif., May 11, 2023 -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended April 1, 2023.

 

First Quarter 2023 Highlights

 

“In addition to receiving FDA clearance in February for our second key laser platform, we were pleased to achieve 19% year-over-year growth in U.S. G6 probe revenue,” said David Bruce, President and CEO. “Although we experienced a modest decline in year-over-year glaucoma probe unit sales resulting from continued international distributor order volatility after a record fourth quarter, we saw strength in international purchases of glaucoma systems. We remain confident in our activities to drive adoption and utilization of our Cyclo G6 glaucoma treatment platform. By leveraging our Sweep Management software and increasing awareness of effective dosing recommendations, we expect clinicians to experience strong clinical outcomes and consistency, leading to increased utilization throughout the year.”

 

First Quarter 2023 Financial Results

 

Revenue for the three months ended April 1, 2023 was $13.7 million compared to $13.4 million during the same period of the prior year. Total product revenue from the Cyclo G6 glaucoma product group was $3.7 million, an increase of 4% compared to the first quarter of 2022, driven by strong probe ASP growth in the U.S. Retina product revenue in the first quarter was $7.2 million compared to $7.3 million in the prior year, a decrease of 1%. Other revenue, which includes royalties, services, and other legacy products, increased 11% to $2.8 million in the first quarter of 2023 compared to the prior year, primarily driven by higher revenue from Other legacy products.

 

Gross profit for the first quarter of 2023 remained essentially unchanged at $5.9 million or a 43.3% gross margin, compared to $6.0 million, or a 44.6% gross margin, in the same period of the prior year. The lower gross margin was the result of higher production overhead.

 

Operating expenses for the first quarter of 2023 were flat at $8.3 million for both the first quarter of 2023 and in the same period of the prior year.

 

Net loss for the first quarter of 2023 was $2.1 million, or $0.13 per share, compared to a net loss of $2.4 million, or $0.15 per share, in the same period of the prior year.

 

Cash and cash equivalents totaled $11.0 million as of April 1, 2023. Cash use of $2.9 million in the first quarter included items unique to the first quarter and cash usage is expected to decrease significantly in the remaining quarters of 2023 as inventory levels decrease.

 

---

Guidance for Full Year 2023

Iridex reiterated its financial outlook for 2023, expecting Cyclo G6 probe sales of 65,000 to 67,000 representing approximately 9% to 12% growth over 2022 and to expand the Cyclo G6 systems installed base by 225 to 250 systems. Total revenue for the full year is expected to be $57 million to $59 million. 2023 total revenue guidance represents growth of approximately 3% to 6% after adjusting for an approximate $1.5 million reduction of Other Revenue royalty income resulting from the expiration of licensed patents.

 

Webcast and Conference Call Information

Iridex’s management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com.

 

About Iridex

Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.

 

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning clinical and commercial momentum, market adoption and expansion, demand for and utilization of the Company's products, financial guidance and results and expected sales volumes. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the fiscal year ended December 31, 2022. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

 

Investor Relations Contact

Philip Taylor

Gilmartin Group

investors@iridex.com

 

 

---

 

IRIDEX Corporation

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

(unaudited)

 

		Three Months Ended
		April 1,				April 2,
		2023				2022
Total revenues		$	13,706			$	13,387
Cost of revenues			7,768				7,410
Gross profit			5,938				5,977
Operating expenses:
Research and development			1,749				2,116
Sales and marketing			4,283				4,300
General and administrative			2,250				1,838
Total operating expenses			8,282				8,254
Loss from operations			(2,344	)			(2,277	)
Other income (expense), net			266				(94	)
Loss from operations before provision for income taxes			(2,078	)			(2,371	)
Provision for income taxes			12				20
Net loss		$	(2,090	)		$	(2,391	)
Net loss per share:
Basic		$	(0.13	)		$	(0.15	)
Diluted		$	(0.13	)		$	(0.15	)
Weighted average shares used in computing net loss per share:
Basic			16,001				15,881
Diluted			16,001				15,881

 

 

---

 

IRIDEX Corporation

Condensed Consolidated Balance Sheets

(In thousands and unaudited)

 

		April 1,				December 31,
		2023				2022
Assets
Current assets:
Cash and cash equivalents		$	11,048			$	13,922
Accounts receivable, net			10,759				9,768
Inventories			11,241				10,608
Prepaid expenses and other current assets			1,650				1,468
Total current assets			34,698				35,766
Property and equipment, net			449				462
Intangible assets, net			1,894				1,977
Goodwill			965				965
Operating lease right-of-use assets, net			1,423				1,665
Other long-term assets			1,551				1,455
Total assets		$	40,980			$	42,290
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable		$	3,669			$	3,873
Accrued compensation			2,813				2,448
Accrued expenses			2,132				1,548
Other current liabilities			882				968
Accrued warranty			196				168
Deferred revenue			2,424				2,411
Operating lease liabilities			1,046				1,037
Total current liabilities			13,162				12,453
Long-term liabilities:
Accrued warranty			124				106
Deferred revenue			11,312				11,742
Operating lease liabilities			472				732
Other long-term liabilities			26				26
Total liabilities			25,096				25,059
Stockholders' equity:
Common stock			169				169
Additional paid-in capital			87,312				86,802
Accumulated other comprehensive loss			(35	)			(24	)
Accumulated deficit			(71,562	)			(69,716	)
Total stockholders' equity			15,884				17,231
Total liabilities and stockholders' equity		$	40,980			$	42,290

 

---